Insider Buying: Mesoblast Limited (ASX:MSB) Insider Acquires A$14,830,544.03 in Stock

Mesoblast Limited (ASX:MSB) insider Gregory George purchased 5,034,129 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The stock was purchased at an average price of A$2.95 ($1.86) per share, with a total value of A$14,830,544.03 ($9,386,420.27).

Mesoblast Stock Performance

The firm has a market capitalization of $2.32 billion, a P/E ratio of -23.29, a P/E/G ratio of 9.56 and a beta of 2.38. The company has a debt-to-equity ratio of 24.76, a current ratio of 1.18 and a quick ratio of 1.82.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.